The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 29, 2020

Filed:

Sep. 25, 2015
Applicants:

The South African Nuclear Energy Corporation Limited, Brits Magisterial District, ZA;

University of Cape Town, Cape Town, ZA;

Inventors:

Cathryn Helena Stanford Driver, Modimolle, ZA;

Jan Rijn Zeevaart, Flaurana, ZA;

Mohamed Iqbal Parker, Cape Town, ZA;

Roger Hunter, Cape Town, ZA;

Assignees:

The South African Nuclear Energy Corporation Limited, Brits Magisterial District, ZA;

University of Cape Town, Cape Town, ZA;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 51/10 (2006.01); A61K 51/04 (2006.01); A61K 51/06 (2006.01); A61K 51/08 (2006.01); A61K 51/12 (2006.01);
U.S. Cl.
CPC ...
A61K 51/1045 (2013.01); A61K 51/0474 (2013.01); A61K 51/0491 (2013.01); A61K 51/0497 (2013.01); A61K 51/065 (2013.01); A61K 51/081 (2013.01); A61K 51/088 (2013.01); A61K 51/121 (2013.01);
Abstract

This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radio nuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.


Find Patent Forward Citations

Loading…